Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ZBIO Zenas BioPharma, Inc. Common Stock
$33.04 -2.16% -0.73
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ZBIO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 2.2B
Enterprise value 1.8B
Trailing PE 1.6313094
Forward PE -6.806867
PEG Ratio 0.019773447272727
Enterprise to EBITDA -6.424
Enterprise to revenue 1759.291
Price to book MRQ 8.129165
Price to sales TTM 2067.4058

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 1.0M
EBITDA -273870016
Diluted EPS TTM -9.63
Total Cash (MRQ) 643.1M
Current ratio (MRQ) 9.933
Operating Cash Flow (TTM) -225972000

ZBIO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ZBIO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.